Adicet Bio, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Adicet Bio announced Phase 1 data on prula-cel (allogeneic gamma-delta CAR-T) in 22 efficacy-evaluable SLE/lupus nephritis patients (16 LN, 6 extra-renal SLE) as of August 28, 2026: 50% achieved complete renal response and 54% achieved DORIS remission at 12 months; all patients discontinued immunosuppressants and all but one tapered steroids to ≤5 mg prednisone; safety profile favorable (no Grade >2 CRS, no ICANS, no IEC-HS). Company plans pivotal trial start-up in Q4 2026, potentially expanding to non-renal SLE based on strong DORIS rate.
Why this rating
Prula-cel is Adicet's lead program in a large market (~70K US patients). Positive Phase 1 efficacy and safety data de-risks pivotal pathway and commercial potential; addresses major unmet need. Relative to $50.5M market cap, successful pivotal could be transformational. However, early-stage data in small cohort; regulatory/execution risk remains.
Price action (we called it positive)
before filing · preread $8.93 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.